Our therapeutic approach targets two specific TLRs (TLR2 & TLR9) known to be key drivers of neuroinflammation found in the brain of patients. Blocking these TLR drivers is expected to disrupt the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback